Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
You may also be interested in...
Novo Nordisk Flaunts Tresiba To Outsmart Sanofi’s Lantus In India
After widening the gap with competitors in the insulin market by a huge margin, Novo Nordisk is preparing to launch Tresiba and take a shot at the long-acting basal insulin market, a stronghold preserved by Sanofi globally. Will Tresiba firmly establish Novo Nordisk as the unquestionable insulin leader?
Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
Novo Nordisk is evaluating new long-acting and quick-acting insulins in clinical trials as competitive pressure looks set to intensify in 2013 for its market-leading GLP-1 agonist, Victoza.
Novo’s Insulin Degludec Faces Advisory Cmte. Scrutiny On Hypoglycemic Benefit, CV Safety
In briefing documents for the Nov. 8 panel review, FDA suggests the clinical trial data do not support Novo Nordisk’s assertion of a hypoglycemia advantage with its new long-acting insulin. Agency also raises concerns about a meta-analysis suggesting an increased cardiovascular risk.